Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics.

Tune L, Coyle JT.

Psychopharmacology (Berl). 1981;75(1):9-15.

PMID:
6117922
2.

Treatment of acute neuroleptic-induced movement disorders.

Tonda ME, Guthrie SK.

Pharmacotherapy. 1994 Sep-Oct;14(5):543-60. Review.

PMID:
7997388
3.

Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.

Kopala LC.

Int Clin Psychopharmacol. 1997 Sep;12 Suppl 4:S11-8. Review.

PMID:
9352341
4.

Abuse potential of anticholinergics.

Dose M, Tempel HD.

Pharmacopsychiatry. 2000 Sep;33 Suppl 1:43-6. Review.

PMID:
11072764
5.

Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.

Gentile S.

J Clin Psychopharmacol. 2007 Feb;27(1):35-45. Review.

PMID:
17224710
6.

Spontaneous and drug-induced movement disorders in schizophrenia.

Kopala LC.

Acta Psychiatr Scand Suppl. 1996;389:12-7. Review.

PMID:
8985472
7.

Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.

Andrew HG.

Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S76-80. Review.

PMID:
7874668
8.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
9.
10.

Extrapyramidal side effects are unacceptable.

Kane JM.

Eur Neuropsychopharmacol. 2001 Oct;11 Suppl 4:S397-403. Review.

PMID:
11587887
11.

Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria.

Gerlach J.

Ann Clin Psychiatry. 2002 Mar;14(1):47-57. Review.

PMID:
12046640
12.

Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.

Shriqui CL.

Can J Psychiatry. 1995 Sep;40(7 Suppl 2):S38-48. Review.

PMID:
8564916
13.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

14.
15.

Novel pharmacological approaches to the treatment of schizophrenia.

Fink-Jensen A.

Dan Med Bull. 2000 Jun;47(3):151-67. Review.

PMID:
10913983
16.

[Extrapyramidal effects of antipsychotic drugs].

Kulisevsky J, Otermin P.

Neurologia. 2003 Jun;18(5):262-8. Review. Spanish.

PMID:
12768512
17.
18.

The relationship of pharmacology to side effects.

Casey DE.

J Clin Psychiatry. 1997;58 Suppl 10:55-62. Review.

19.

Effects of newer antipsychotics on extrapyramidal function.

Tarsy D, Baldessarini RJ, Tarazi FI.

CNS Drugs. 2002;16(1):23-45. Review. Erratum in: CNS Drugs. 2003;17(3):202.

PMID:
11772117
20.

Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia.

Arana GW, Goff DC, Baldessarini RJ, Keepers GA.

Am J Psychiatry. 1988 Aug;145(8):993-6. Review.

PMID:
2899403
Items per page

Supplemental Content

Write to the Help Desk